FindTrial
Sign In

Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Alpha-Glucosidase Inhibitor or Pioglitazone in Patients with Type 2 Diabetes

Efficacy and Long-Term Safety of SK-0403 as Add-on Therapy to Alpha-Glucosidase Inhibitor or Pioglitazone in Patients with Type 2 Diabetes

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220767
Enrollment
Unknown
Registered
2009-07-07
Start date
2009-07-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

investigational material(s) Generic name etc : SK-0403 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Sponsors

SANWA KAGAKU KENKYUSHO Co., Ltd.
Lead Sponsor
Kowa Company, Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who have inadequate glycemic control on alpha-glucosidase inhibitor or pioglitazone therapy HbA1C of >= 6.5%, but < 10.0% measured during the run-in period

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes mellitus Patients require insulin or oral antidiabetic drug therapy other than alpha-glucosidase inhibitor or pioglitazone Patients with, or a history of, clinically significant cardiac, renal, hepatic, pulmonary, pancreatic and macrovascular disease Patients have a known allergy or hypersensitivity to alpha-glucosidase inhibitor or pioglitazone

Design outcomes

Primary

MeasureTime frame
Efficacy and Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026